Micro-X (ASX:MX1) reported about A$15.1 million in Revenue for the financial year ended June 2026. The result includes imaging products and contracted development activity across the business. Operating losses and funding requirements remain relevant alongside revenue.

Lightweight X-ray Technology for Mobile Use

Micro-X designs and manufactures compact, lightweight X-ray systems built around proprietary carbon nanotube emitter technology, which allows imaging hardware to be made significantly smaller and lighter than conventional X-ray tube-based systems. The company's products target mobile and point-of-care imaging use cases — including hospital ward-based chest imaging and, through its defence and security-related programmes, portable imaging for field and screening applications — where the size and weight of traditional X-ray equipment is a practical barrier.

Revenue Growth Alongside Repeated Capital Raises

Micro-X’s FY26 Annual Report recorded A$15.087 million of revenue from ordinary activities, compared with A$13.053 million in FY25, and a loss after tax of A$9.876 million. Its carbon-nanotube X-ray technology underpins products and projects across medical and security imaging. The size and terms of capital raisings provide more information about funding than quotations of newly issued securities alone.

What the Evidence Means

The FY26 revenue figure combines multiple activities and cannot by itself establish the commercial scale of portable medical-device sales. The annual loss shows that revenue had not yet covered total costs. Product orders, segment detail and Operating Cash Flow are more direct measures of progress than a count of share quotations.

A Niche Position Within Medical Imaging

Micro-X occupies a narrow but technically differentiated niche within the broader medical and security imaging sector, competing less on price against large incumbent imaging manufacturers and more on the practical advantages of weight and portability that its carbon nanotube emitter technology provides. That differentiation is most valuable in settings where conventional X-ray equipment is genuinely impractical — mobile ward imaging, field and defence applications, and space-constrained screening environments — rather than as a wholesale replacement for fixed hospital imaging infrastructure, which shapes both the size of its addressable market and the realistic pace of revenue growth.

Risks and Milestones Ahead

Risks include the typically long sales cycles associated with hospital procurement and defence-related contracts, competitive pressure from larger, better-capitalised imaging equipment manufacturers, and continued dilution risk if revenue growth does not outpace cash consumption. Foreign exchange movements are also relevant, given a portion of Micro-X's contract revenue is denominated in US dollars while its cost base is largely in Australian dollars.

Investors should watch for further revenue disclosures in upcoming quarterly reports, confirmation of order backlogs or new contract wins in either the medical or defence and security segments, and whether the pace of new share issuances slows as revenue scales.